<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225715</url>
  </required_header>
  <id_info>
    <org_study_id>WV41073</org_study_id>
    <secondary_id>2019-002086-35</secondary_id>
    <nct_id>NCT04225715</nct_id>
  </id_info>
  <brief_title>A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B</brief_title>
  <acronym>Piranga</acronym>
  <official_title>A Phase II, Randomised, Adaptive, Open-Label Platform Trial To Evaluate Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study designed to evaluate the safety, tolerability and efficacy of New Molecular&#xD;
      Entity (NME) combination therapies in Chronic Hepatitis B (CHB) participants with preserved&#xD;
      liver function and without significant fibrosis/cirrhosis. The platform design allows&#xD;
      comparison of multiple NME combination therapies against a common control, and introduction&#xD;
      of additional treatment arms at later study time points. Each arm will consist of a screening&#xD;
      phase (up to 8 weeks), treatment phase (up to 48 weeks) and post-treatment follow-up phase&#xD;
      (48 weeks). The safety and efficacy will be monitored throughout the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2020</start_date>
  <completion_date type="Anticipated">August 19, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 4, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Hepatitis B Surface Antigen (HBsAg) loss at 24 weeks post-EOT (End Of Treatment)</measure>
    <time_frame>Up to 72 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBsAg loss</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBsAg seroconversion</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Hepatitis B Early Antigen (HBeAg) loss (baseline HBeAg-positive participants).</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBeAg seroconversion (baseline HBeAgpositive participants)</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBV DNA &lt; lower limit of quantification (LLOQ), &lt;200 IU/mL and &lt;2,000 IU/mL</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quantitative HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc, HBcrAg, HBV RNA, and HBV DNA levels over time (IU/mL)</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) (TLR7) (IU/mL)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK (CpAM) (IU/mL)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK (NUC) (IU/mL)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK (siRNA) (IU/mL)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum PK (PEG-IFN) (IU/mL)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-siRNA Antibodies</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-PEG-IFN Antibodies</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Nucleos(t)ide (NUC) Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will continue their background NUC therapy for the 48-week treatment period. At the end of the treatment period, in line with current CHB treatment guidelines, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CpAM (RO7049389) + TLR7 (RO7020531) + NUC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7049389 (600 mg once daily [QD]) in addition to their background NUC therapy for the 48-week treatment period. RO7020531 (150 mg once every other day [QOD]) will be administered during Weeks 1-12 and Weeks 25-36. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>siRNA (RO7445482) + NUC [1]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7445482 (Dose 1) in addition to their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>siRNA (RO7445482) + NUC [2]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7445482 (Dose 2) in addition to their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>siRNA (RO7445482) + PEG-IFN + NUC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7445482 (Dose 2) in addition to their background NUC therapy for the 48-week treatment period. PEG-IFN will be administered at a dose of 180 Î¼g once weekly (QW) for 48 weeks. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>siRNA (RO7445482) + CpAM (RO7049389) + NUC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7445482 (Dose 2) and RO7049389 (600 mg QD) in addition to their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>siRNA (RO7445482) + TLR7 (RO7020531) + NUC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7445482 (Dose 2) in addition to their background NUC therapy for the 48-week treatment period. RO7020531 (150 mg QOD) will be administered during Weeks 13-24 and Weeks 37-48 (i.e., 2 treatment cycles of 12 weeks' duration each and 42 doses of RO7020531 for each cycle). At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleos(t)ide (NUC)</intervention_name>
    <description>Nucleos(t)ide (NUC) will be administered orally</description>
    <arm_group_label>CpAM (RO7049389) + TLR7 (RO7020531) + NUC</arm_group_label>
    <arm_group_label>Nucleos(t)ide (NUC) Control Arm</arm_group_label>
    <arm_group_label>siRNA (RO7445482) + CpAM (RO7049389) + NUC</arm_group_label>
    <arm_group_label>siRNA (RO7445482) + NUC [1]</arm_group_label>
    <arm_group_label>siRNA (RO7445482) + NUC [2]</arm_group_label>
    <arm_group_label>siRNA (RO7445482) + PEG-IFN + NUC</arm_group_label>
    <arm_group_label>siRNA (RO7445482) + TLR7 (RO7020531) + NUC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CpAM (RO7049389)</intervention_name>
    <description>CpAM (RO7049389) will be administered orally</description>
    <arm_group_label>CpAM (RO7049389) + TLR7 (RO7020531) + NUC</arm_group_label>
    <arm_group_label>siRNA (RO7445482) + CpAM (RO7049389) + NUC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TLR7 (RO7020531)</intervention_name>
    <description>TLR7 (RO7020531) will be administered orally</description>
    <arm_group_label>CpAM (RO7049389) + TLR7 (RO7020531) + NUC</arm_group_label>
    <arm_group_label>siRNA (RO7445482) + TLR7 (RO7020531) + NUC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>siRNA (RO7445482)</intervention_name>
    <description>siRNA (RO7445482) will be administered subcutaneously</description>
    <arm_group_label>siRNA (RO7445482) + CpAM (RO7049389) + NUC</arm_group_label>
    <arm_group_label>siRNA (RO7445482) + NUC [1]</arm_group_label>
    <arm_group_label>siRNA (RO7445482) + NUC [2]</arm_group_label>
    <arm_group_label>siRNA (RO7445482) + PEG-IFN + NUC</arm_group_label>
    <arm_group_label>siRNA (RO7445482) + TLR7 (RO7020531) + NUC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-IFN</intervention_name>
    <description>PEG-IFN will be administered subcutaneously</description>
    <arm_group_label>siRNA (RO7445482) + PEG-IFN + NUC</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index between 18 and 32 kg/m2 inclusive.&#xD;
&#xD;
          -  Participants with Chronic Hepatitis B (CHB) infection (HBsAg positive for &gt;=6 months)&#xD;
             who are on established NUC (entecavir or tenofovir alafenamide/disoproxil fumarate)&#xD;
             monotherapy for &gt;=12 months, having received the same NUC therapy for &gt;=3 months prior&#xD;
             to screening.&#xD;
&#xD;
          -  HBV DNA below the lower LLOQ or &lt; 20 IU/mL for &gt; 6 months prior to screening and&#xD;
             confirmed at screening.&#xD;
&#xD;
          -  Alanine transaminase (ALT) &lt;=1.5 x upper limit of normal (ULN) for &gt; 6 months prior to&#xD;
             screening and confirmed at screening.&#xD;
&#xD;
          -  Female Participants: Eligible to participate if she is not pregnant, not breastfeeding&#xD;
             and agrees to remain abstinent (refrain from heterosexual intercourse) or use highly&#xD;
             effective contraceptive methods.&#xD;
&#xD;
          -  Male Participants: During the treatment period and for at least 6 months after the&#xD;
             final dose of study treatment, agrees to remain abstinent (refrain from heterosexual&#xD;
             intercourse), use contraceptive measures and refrain from donating sperm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Co-infection with other pathogens such as Hepatitis A, C, D and E or Human&#xD;
             Immunodeficiency Virus (HIV).&#xD;
&#xD;
          -  History of cirrhosis or current evidence of significant liver fibrosis or cirrhosis or&#xD;
             decompensated liver disease.&#xD;
&#xD;
          -  History of or suspicion of Hepatocellular Carcinoma (HCC).&#xD;
&#xD;
          -  Thyroid disease poorly controlled on prescribed medications or clinically relevant&#xD;
             abnormal thyroid function tests.&#xD;
&#xD;
          -  Clinically significant disease other than CHB that, in the opinion of the&#xD;
             Investigator, makes the participant unsuitable for the study.&#xD;
&#xD;
          -  Pre-existing cardiac disease that in the opinion of the investigator would increase&#xD;
             the risk for the participant to take part in the study.&#xD;
&#xD;
          -  History of alcohol abuse and/or drug abuse within one year of randomization.&#xD;
&#xD;
          -  History of having received (in the last 6 months) or currently receiving any systemic&#xD;
             antineoplastic (including radiation) or immunosuppressive (including biologic&#xD;
             immunosuppressors) or immune modulating treatment.&#xD;
&#xD;
          -  Currently taking, or have received within 3 months of Day 1, systemic corticosteroids.&#xD;
&#xD;
          -  Electrocardiogram (ECG) with clinically significant abnormalities.&#xD;
&#xD;
          -  Previous treatment with an investigational agent for Hepatitis B (HBV) within 6 months&#xD;
             prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID: WV41073 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun City</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai City</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital, Fudan University</name>
      <address>
        <city>Shanghai City</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon; Chir 2</name>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital de la Croix-Rousse - Groupement Hospitalier Nord; Pharmacie / Secteur Essais Cliniques</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Brabois Adultes; Service MÃ©decine Interne HÃ©matologie</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chuncheon Sacred Heart Hospital</name>
      <address>
        <city>Gangwon-Do</city>
        <zip>200-704</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>ChungAng University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center / Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Limited</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Middlemore Clinical Trials</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Do Meixoeiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall dHebron; Oncology</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Montecelo</name>
      <address>
        <city>Pontevedra</city>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Chang Hua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital; Pharmacy</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital; Internal Medicine</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hivnat; Thai Red Cross Center</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>King College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

